Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elisabeth Longchamp"'
Autor:
Hélène Salvator, Amparo Buenestado, Marion Brollo, Emmanuel Naline, Tatiana Victoni, Elisabeth Longchamp, Hermann Tenor, Stanislas Grassin-Delyle, Philippe Devillier
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background: Roflumilast is an option for treating patients with severe COPD and frequent exacerbations despite optimal therapy with inhaled drugs. The present study focused on whether the phosphodiesterase (PDE) 4 inhibitor roflumilast and its active
Externí odkaz:
https://doaj.org/article/35f2121e1b8d4ebebc14487580452dbb
Autor:
Carole Vignals, Joseph Emmerich, Hugues Begueret, Dea Garcia-Hermoso, Guillaume Martin-Blondel, Adela Angoulvant, Damien Blez, Patrick Bruneval, Sophie Cassaing, Emilie Catherinot, Pierre Cahen, Cécile Moluçon-Chabrot, Carole Chevenet, Laurence Delhaes, Lélia Escaut, Marie Faruch, Frédéric Grenouillet, Fabrice Larosa, Lucie Limousin, Elisabeth Longchampt, François Mellot, Céline Nourrisson, Marie-Elisabeth Bougnoux, Olivier Lortholary, Antoine Roux, Laura Rozenblum, Mathilde Puges, Fanny Lanternier, Didier Bronnimann
Publikováno v:
Emerging Infectious Diseases, Vol 30, Iss 6, Pp 1077-1087 (2024)
Scedosporium spp. and Lomentospora prolificans are emerging non-Aspergillus filamentous fungi. The Scedosporiosis/lomentosporiosis Observational Study we previously conducted reported frequent fungal vascular involvement, including aortitis and perip
Externí odkaz:
https://doaj.org/article/2cc204870acd4303b99d379cda499716
Autor:
Jean-Paul Vernant, Louis-Jean Couderc, Elisabeth Longchamp, Colas Tcherakian, Madelina Uzunov, Nathalie Dhedin, Elisabeth Rivaud
Publikováno v:
B40. INTERSTITIAL LUNG DISEASE: EPIDEMIOLOGY AND OUTCOMES.
Autor:
Julia Mercier, Claire Calmel, Julie Mésinèle, Erika Sutanto, Fatiha Merabtene, Elisabeth Longchampt, Edouard Sage, Anthony Kicic, Pierre-Yves Boëlle, Harriet Corvol, Manon Ruffin, Loïc Guillot
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Cystic fibrosis (CF), due to pathogenic variants in CFTR gene, is associated with chronic infection/inflammation responsible for airway epithelium alteration and lung function decline. Modifier genes induce phenotype variability between people with C
Externí odkaz:
https://doaj.org/article/d891003e969b491da4d14726cd750efe
Autor:
Louise Sebane, Mostafa El-Hajjam, Philippe Puyo, Elisabeth Longchampt, Etienne Giroux Leprieur
Publikováno v:
BMC Surgery, Vol 18, Iss 1, Pp 1-3 (2018)
Abstract Background Lepidic predominant adenocarcinoma is characterized by frequent refractory hypoxemia due to intrapulmonary shunting. Severe hypoxemia can induce perioperative complications in case of thoracic surgery. Case presentation We report
Externí odkaz:
https://doaj.org/article/432355162d554e1cb4cda2b3f129fff1
Autor:
Kinan Drak Alsibai, Sophie Vacher, Didier Meseure, Andre Nicolas, Marick Lae, Anne Schnitzler, Walid Chemlali, Jerome Cros, Elisabeth Longchampt, Wulfran Cacheux, Geraldine Pignot, Celine Callens, Eric Pasmant, Yves Allory, Ivan Bieche
Publikováno v:
Non-Coding RNA, Vol 5, Iss 3, p 44 (2019)
The CDKN2B-AS1 gene, also called ANRIL, is located at the human CDKN2A/B locus at 9p21.3 and transcribed by RNA polymerase II into a long non-coding RNA of 3834 bp. The CDKN2B-AS1 gene overlaps a critical region of 125 kb covering the CDKN2B gene. Th
Externí odkaz:
https://doaj.org/article/0e7b685dc6924334b6e832f8b7292470
Autor:
Patrick R. Benusiglio, Sophie Gad, Christophe Massard, Edith Carton, Elisabeth Longchampt, Tiffany Faudot, Jérôme Lamoril, Sophie Ferlicot
Publikováno v:
F1000Research, Vol 3 (2014)
Patients with the Birt-Hogg-Dubé cancer susceptibility syndrome are at high risk of developing renal cell carcinoma, pulmonary cysts and pneumothorax, and skin lesions called fibrofolliculomas. Here we report the case of a Birt-Hogg-Dubé patient wi
Externí odkaz:
https://doaj.org/article/e6fc9c8ef7e2418da70d4401ebd9d3ea
Autor:
Amparo Buenestado, Marie-Camille Chaumais, Stanislas Grassin-Delyle, Paul-André Risse, Emmanuel Naline, Elisabeth Longchampt, Hermann Tenor, Philippe Devillier
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74640 (2013)
BackgroundRoflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of
Externí odkaz:
https://doaj.org/article/de9a65066ccf468bb4e118f196475e88